Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep17 | Adrenal and Cardiovascular Endocrinology | ECE2020

A double-blind, randomized, placebo-controlled phase 3 study to assess the efficacy and safety of relacorilant, a selective glucocorticoid receptor modulator, in patients with hypercortisolism due to cortisol-secreting adrenal adenoma(s)/hyperplasia

Chiodini Iacopo , Grauer Andreas , Moraitis Andreas , Terzolo Massimo

Relacorilant is a highly selective glucocorticoid receptor modulator that antagonizes the effects of excess cortisol while showing no significant affinity for the mineralocorticoid and progesterone receptors. In a Phase 2 study in patients with endogenous hypercortisolism, relacorilant demonstrated improvements in glycemic and hypertension control with no treatment-related hypokalemia or antiprogesterone effects. An international, multicenter, Phase 3 clinical trial, using ran...

ea0070aep30 | Adrenal and Cardiovascular Endocrinology | ECE2020

Excess glucocorticoid activity may suppress tumor immune activity in adrenocortical carcinoma

Greenstein Andrew , Amir Habra Mouhammed , Mura Marzena , Biernat Paweł , Piatek Marek J , Grauer Andreas , Peacock Shepherd Stacie

Introduction: Excess glucocorticoid (GC) activity has been implicated in the pathophysiology of multiple cancer types. For instance, approximately half of adrenocortical carcinoma (ACC) patients exhibit excess GC (GC+). This provides a unique opportunity to study correlates of GC activity, such as a possible suppression of tumor immune response and immune checkpoint inhibitor (ICI) efficacy due to the broad immunosuppressive effects of GC. ACC multi-omics data can be used ...